By Colin Kellaher 



  Vertex Pharmaceuticals Inc. on Friday said the European Commission approved Kaftrio in combination with ivacaftor to treat people ages 12 and over with cystic fibrosis. 


  The Boston drug maker said the approval covers the combination in patients with one F508del mutation and one minimal function mutation, or two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene. 


  The European Medicines Agency's Committee for Medicinal Products for Human Use in June recommended approval of the combination. 


  Write to Colin Kellaher at colin.kellaher@wsj.com